Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.
Sarah Ferguson, MD
Advertisement
Articles by Sarah Ferguson, MD
Advertisement
Latest Updated Articles
Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer SurgeryPublished: November 1st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5